ZNF620 and cancer: Specifically, 17 out of the 20 enriched genes (upregulated DEGs: TPSAB1, TPSB2, C1QTNF3, PIEZO2, CTSG, COL1A2, COL1A1, COL3A1, OSR2, ABI3BP, MMP2, GXYLT2, COL5A1, ADAMTS2; downregulated DEGs: ZNF620, CCDC157, RP1) exhibited higher expression levels in PR-positive cancer tissue compared to PR-negative counterparts, while only 3 genes (upregulated DEG: CCL18; downregulated DEGs: SLC4A11, LAMA1) displayed heightened enrichment in PR-negative tissue (Figure 3A,B).